Ochsner Medical Center

Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gilead and received grants from Bristol‐Myers Squibb and Roche. Dr. Brown consults and received grants from Gilead. Dr. Bzowej received grants from Gilead, Allergan and Cirius. Dr. Terrault received grants from Gilead and Bristol‐Myers Quibb. Dr. Wong is a member of the United States Preventive Services Task Force (USPSTF). This article does not necessarily represent the views and policies of the USPSTF. The funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. This practice guidance was approved by the American Association for the Study of Liver Diseases on December 4, 2017. Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B1 and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients. The AASLD 2018 Hepatitis B Guidance provides a data‐supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B. It differs from the published 2016 AASLD guidelines, which conducted systematic reviews and used a multidisciplinary panel of experts to rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations Assessment, Development and Evaluation system in support of guideline recommendations.1 In contrast, this guidance document was developed by consensus of an expert panel, without formal systematic review or use of the Grading of Recommendations Assessment, Development, and Evaluation system. The 2018 guidance is based upon the following: (1) formal review and analysis of published literature on the topics; (2) World Health Organization guidance on prevention, care, and treatment of CHB5; and (3) the authors’ experience in acute hepatitis B and CHB. Intended for use by health care providers, this guidance identifies preferred approaches to the diagnostic, therapeutic, and preventive aspects of care for patients with CHB. As with clinical practice guidelines, it provides general guidance to optimize the care of the majority of patients and should not replace clinical judgement for a unique patient. This guidance does not seek to dictate a “one size fits all” approach for the management of CHB. Clinical considerations may justify a course of action that differs from this guidance. Interim Data Relevant to the AASLD 2018 Hepatitis B Guidance Since the publication of the 2016 AASLD Hepatitis B Guidelines, tenofovir alafenamide (TAF) has been approved for treatment of CHB in adults. TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg‐IFN; Tables 1 and 2)6 (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B). Additionally, studies on the use of TDF for prevention of mother‐to‐child transmission led to TDF being elevated to the level of preferred therapy in this setting (section 1C of Screening, Counseling, and Prevention of Hepatitis B). Table 1 - Approved Antiviral Therapies in Adults and Children Drug Dose in Adultsa Use in Childrena Pregnancy Categoryb Potential Side Effectsb Monitoring on Treatmentc Preferred Peg‐IFN‐α‐2a (adult) IFN‐α‐2b (children) 180 mcg weekly ≥1 year dose: 6 million IU/m2 three times weeklyd C Flu‐like symptoms, fatigue, mood disturbances, cytopenia, autoimmune disorders in adults, anorexia and weight loss in children Complete blood count (monthly to every 3 months) TSH (every 3 months) Clinical monitoring for autoimmune, ischemic, neuropsychiatric, and infectious complications Entecavir 0.5 mg dailye ≥2 years dose: weight‐based to 10‐30 kg; above 30 kg: 0.5 mg dailye C Lactic acidosis (decompensated cirrhosis only) Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Tenofovir dipovoxil fumarate 300 mg daily ≥12 years B Nephropathy, Fanconi syndrome, osteomalacia, lactic acidosis Creatinine clearance at baseline If at risk for renal impairment, creatinine clearance, serum phosphate, urine glucose, and protein at least annually Consider bone density study at baseline and during treatment in patients with history of fracture or risks for osteopenia Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Tenofovir alafenamide 25 mg daily — There are insufficient human data on use during pregnancy to inform a drug‐associated risk of birth defects and miscarriage. Lactic acidosis Lactic acid levels if clinical concern Assess serum creatinine, serum phosphorus, creatinine clearance, urine glucose, and urine protein before initiating and during therapy in all patients as clinically appropriate Test for HIV before treatment initiation Nonpreferred Lamivudine 100 mg daily ≥2 years dose: 3 mg/kg daily to max 100 mg C Pancreatitis Lactic acidosis Amylase if symptoms are present Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Adefovir 10 mg daily ≥12 years C Acute renal failure Fanconi syndrome Lactic acidosis Creatinine clearance at baseline If at risk for renal impairment, creatinine clearance, serum phosphate, urine glucose, and urine protein at least annually Consider bone density study at baseline and during treatment in patients with history of fracture or risks for osteopenia Lactic acid levels if clinical concern Telbivudine 600 mg daily — B Creatine kinase elevation and myopathy Peripheral neuropathy Lactic acidosis Creatine kinase if symptoms are present Clinical evaluation if symptoms are present Lactic acid levels if there is clinical concern aDose adjustments are needed in patients with renal dysfunction.bIn 2015, the U.S. Food and Drug Administration replaced the pregnancy risk designation by letters A, B, C, D, and X with more specific language on pregnancy and This is being in and to TAF includes is not approved for children with chronic hepatitis B, is approved for treatment of chronic hepatitis may using this for children with chronic The of treatment in is is 1 mg daily if the is or if Table - of Approved Antiviral Therapies in Adults with Chronic Hepatitis B and Tenofovir Tenofovir to loss — — loss 3 years 1 Entecavir Tenofovir Tenofovir to loss 6 3 years 6 of of 3 years of years of for for and tenofovir disoproxil for tenofovir for for and tenofovir disoproxil for tenofovir by and for and is a that of to HBV TAF is more TDF in and the to more a to used with and renal and bone 3 of hepatitis B patients with to TAF 25 mg daily or TDF 300 mg daily in a with serum HBV in in loss in and hepatitis B loss in in the TAF and TDF that and serum HBV and and and in TAF and TDF a 3 of patients with to TAF 25 mg daily or TDF 300 mg daily in a in in the TAF and TDF in serum HBV in of TAF patients and of TDF with 1 The approved of TAF is 25 mg with needed creatinine clearance is In 3 TAF TDF in bone density and renal at of In the in the rate was for TAF the was in TDF patients In the in the rate was in TAF the for TDF patients was In and bone density the in bone density for TAF TDF was for patients and in patients In human virus TAF TDF therapy for to that TAF a on bone density and renal with patients on TAF TDF or treatment of renal complications data in patients are with to the on clinical as renal and fracture the of TAF with evidence of led to the preferred HBV for patients studies of from TDF to TAF from the HIV In studies of to a to TAF TDF treatment of an was with in renal the and bone studies that TAF has a TDF and in studies of to 1 Screening, Counseling, and Prevention of Hepatitis B The of the of hepatitis B. Chronic acute is by the of for at least 6 The of with of persons as as to and as In developed the is from or and in with HBV is by and and by by and children in In HBV is transmission the of chronic transmission in the United in children of not appropriate HBV at The majority of children and with CHB in the United States are or HBV the for The risk of chronic HBV acute from in of to in and children to in In persons are more to chronic HBV acute Table 3 at risk for CHB should for HBV and if and to hepatitis B should used for to hepatitis B for as as are for and to from previous HBV HBV does not to Table 3 - at for HBV in of or HBV of and and and and of and of and and and and and and persons not as an in with HBV with immunosuppressive therapy, including to and for or with elevated or of of or with renal including and to with chronic with and of are not in a during the previous 6 evaluation or treatment for a Health care and at risk for to blood or and of for to with or of HBV are the of blood or that of persons with are years of for with are should hepatitis B if Table - of for HBV Test Chronic hepatitis B and management needed HBV management or or immunosuppressive therapy HBV or HBV if if not from of or and not persons may for not may or may not with the on or the risk The of for and for a of to populations, the is previous to HBV the majority of persons from acute HBV in and to been with HBV for before In the the risk of or cirrhosis to HBV is In the persons are at risk of with an rate that to to with chronic HBV with levels more if are if are and are in with of HBV or HIV or hepatitis C virus with more specific may a in persons from with risk for HBV and more may the of HBV during the of acute hepatitis persons should for of to of the risk for HBV for in blood if in Since the the of has to in blood and in with HIV or to or immunosuppressive therapy are at risk for if HBV and should for The majority of for not HBV with specific to or to hepatitis B and HBV with a HBV a HBV does not levels of HBV in blood in an on the and of the used and HBV in the study the of patients an to HBV with the majority a to hepatitis B to persons without HBV for all in Table should HBV to HBV with to levels 3 or data that may the of using an with HBV the of hepatitis B transmission the clinical of the patient. persons are for for are at risk of HBV the risk or immunosuppressive are or in Screening, Counseling, and Prevention of Hepatitis B, all persons are for or without should at risk for HBV in this Guidance on for Hepatitis B should using and is in all persons in with a of persons not as in with HBV persons immunosuppressive therapy, and the in Table persons should for to is not is an in patients HIV are to or and immunosuppressive or renal and in blood if Screening, Counseling, and Prevention of Hepatitis B, B, Patients with chronic HBV should and prevention of transmission as as the of specific been to on the of CHB syndrome and to of more of for and more for are with risk of cirrhosis and the risk of of are the approach is to or with CHB should hepatitis if not persons should transmission to Table of risk of HBV and should if for HBV serological or not been or not the should of HBV from health care to patients has been to in persons with CHB are the for and Prevention that should seek and from an expert review If serum HBV therapy is and of is if serum HBV is to and that Since the U.S. of has that it is for and to are to special to for children in the in and Table - Recommendations for Prevention of of HBV to and Use during if is not or is not or and blood with or Children and Adults in all including not from or and should not from children and and Guidance on of persons should prevention of transmission of HBV to and are should not from or practice hepatitis B. and of are to seek and from an expert review panel at should not if serum level may if level is and special are for children in as and are to or use of is in of weight and treatment of including of and are to development of syndrome and Guidance on of and or for is not in patients HIV or are to therapy or immunosuppressive are without are not at risk of transmission of or to are for and are from an with with risk for HBV should the of hepatitis B are for and risk for hepatitis B are not for are HIV or should for with CHB should to with the prevention of mother‐to‐child Hepatitis B and HBV should to Antiviral therapy in the is for with serum HBV of hepatitis with or without the of to been It has been that the in levels of the is to the therapy that has been used to the are and of acute failure been in the therapy from to not in the AASLD guideline recommendation that therapy for prevention of mother‐to‐child transmission at the of or to previous systematic review of therapy in the a in transmission of with or TDF is the preferred to and for with the of TDF treatment in the in risk of mother‐to‐child transmission of hepatitis B with TDF in with a level of HBV kinase levels more in untreated in as clinically studies in the of or data on bone from studies of therapy in a previous study of to bone the study at years of during as the risk of HBV in the is studies including and that the risk of HBV transmission by is more the risk of mother‐to‐child transmission of HBV was in with a level with not the risk of mother‐to‐child transmission the of in not clinical studies support the of during HBV is and during In of the to as without the of has been to and in Chronic HBV does not the of pregnancy the has cirrhosis or care is to the and to that the and HBV of Guidance on of in Pregnancy HBV is in and are not to or with HBV should this as during pregnancy should to care for HBV or for if and of for for HBV therapy should without HBV in the should treatment to mother‐to‐child are not on therapy as as at or should for to 6 for hepatitis and should to for The risk of mother‐to‐child transmission of HBV with should in the risk of in with with cirrhosis should in and with TDF to of as during pregnancy should for HBV or and HBV if is not Recommendations for are in the for and Prevention and on is for at risk of as of of persons with chronic and including with of patients is that in are at a risk of to are not in if the is as studies that serological patients as persons on or with chronic including a is the 10 are to the a of and is are including with on or with use of a of has been to the of patients the level of the of HBV with or without is for of or to or This includes and should of are on the during which is the is to for and for The for and Prevention has updated guidelines for and for health care to is should of may of should and HBV of birth by the for at 1 of The should not before of HBV should used for or 6 Guidance for Prevention of of Hepatitis B With Chronic HBV HBV an and are as a at and 6 or without hepatitis at and to 30 by a at used for the hepatitis and B for a at and 1 has been approved for and of persons are for and should HBV of should and HBV at and the of should at of of persons with chronic HBV chronic and persons with should for to the the of to the a is with a used for including with of is annually for chronic or are not if of to in patients and are and of Chronic Hepatitis B The for CHB and clinical to HBV are in Table The of for at least 6 the of As HBV is not to the are to with chronic and viral clearance, to the development of cirrhosis and CHB is a and with CHB clinical with levels of serum HBV and HBV The levels of serum and HBV as as are of that inform for treatment initiation as as treatment of and levels are needed to treatment Additionally, of using or as are in and with treatment Table 6 - and for Chronic Hepatitis B Chronic Hepatitis B (CHB) present for HBV from to and levels are in and are in CHB. or elevated levels Liver chronic hepatitis with CHB present for levels are million or elevated Liver or and CHB present for HBV in CHB and in CHB or elevated levels Liver or chronic hepatitis with or and with or without CHB present for HBV levels Liver of or levels of HBV loss of HBV in or patients immunosuppressive therapy for a a in HBV to baseline an level of HBV a baseline is and from to for patients Hepatitis times baseline and HBV and hepatitis loss of in a was loss of and of in a was and of in a was loss of in a was with levels and of clinical or evidence of viral in serum HBV from during treatment in a an virological and is for management of persons without cirrhosis are or of for in are to for and for of for of for and 25 for is to management of for in are to for and for of management of a for of for and 25 for is in of the been This to a elevation is the for of in the of treatment that the elevation may to as or 3 in of Chronic Hepatitis B of serum HBV is a in the evaluation of patients with CHB and in the of the of used in clinical practice with a of and a to patients with CHB levels that may from to monitoring of levels is more in and in the for patients with CHB levels and with CHB levels with levels in with CHB in CHB. The is an which the of chronic and been in patients with the of levels in the of of and of treatment HBV of HBV been The of HBV HBV been in the United with A, B, and C being HBV may an in the of as as to is with of and loss with from that HBV B is with at an more a rate of to and a rate of development with from that on in persons with HBV C in with HBV A, B, D, or In a of has been in persons with C or in with the The to led to development of and to and it that from as a for viral levels by in and by of or with The levels of are in patients In and HBV CHB. the of with to levels been with to cirrhosis and clearance in patients with a viral treatment of and provides a at in of for and for the of at that loss or HBV treatment In of the patients with B and C at and treatment of of the patients and of HBV at a treatment as by a level treatment of a in loss of and level with a 3 years or more of Hepatitis B in patients are patients on therapy, the of is virological which is as a in serum HBV from during treatment in a an virological with that during to a in serum HBV that may with in specific in the The and an level Guidance on Use of and is to treatment including initiation of treatment and evaluation of a to in patients is not for the or of patients with CHB. HBV in patients being for therapy, that and B are with of loss C and D, it is not for or of patients with CHB. for viral in patients is not in patients with treatment with on therapy, or experience virological during of Patients on Antiviral Treatment Patients not for therapy monitoring to the for therapy the AASLD 2016 HBV HBV patients should at to monitoring should levels Patients with with levels a to of elevated levels times the of for and for should for Liver should in patients with or elevated in patients been with HBV from a Patients with or or for may used in of to for of Liver are more serum to or in or if levels of as by elevated are HBV patients should with every 3 during the year to that are in the and every If the level monitoring should more In for or evaluation for should that a with HBV may patients in the in which or levels are CHB and In and HBV CHB from CHB with a and of and more of the specific is CHB loss has been to at the rate of this does not at a In a study of patients with CHB in of loss 10 years and to 25 loss in to therapy, being more with with of to cirrhosis or patients of are present or the risk of if loss in patients years or in with cirrhosis or with or hepatitis virus of with of has been This is from in which and are Guidance for Monitoring Patients With Chronic HBV on Treatment that CHB is a persons are not treatment should to an for treatment has patients with should for at to If levels above along with HBV should more should every Patients are with levels and levels times the for for should to years and at a of Liver the of and If the or or or treatment is to are and or If treatment is Patients are with levels and elevated levels times the should to are years and at a of Liver the of and If the or or or treatment is to are and or If treatment is Patients are with and HBV should for and HBV every 3 during the year to CHB. and levels should at to If are a monitoring levels above the along with HBV should more (every In persons with HBV elevated of should not or or autoimmune with CHB should for loss of In persons and monitoring are should if the has a member with or a of years for and years for been with HBV from a for The AASLD 2018 Practice Guidelines on has been the as for and the and of are of The guideline for of persons at risk of with every 6 There was insufficient evidence for or the of every 6 to is not in is or is an is if the risk of is this all patients with cirrhosis patients without and history should with a risk of persons with or HIV and with this there is insufficient evidence to in children in children with cirrhosis or with a member with Guidance for in patients with cirrhosis should with with or without every 6 at risk for or years and years of persons with a member with a history of or persons with should with with or without every 6 There are insufficient data to for in it is to children and with or cirrhosis and with a member with using with or without every 6 persons at risk for are in is not with every 6 should 6 of Chronic HBV in As with with the treatment are to risk of to and including In the viral for by and If is treatment of should If HBV is treatment is by the HBV and levels treatment of virus may to in the of the and monitoring during and treatment is to for viral In the the treatment of for patients with HBV and was and for on the of and HBV with this a in serum HBV an and HBV in patients with HBV before treatment been with and therapy has been to levels in and to with HBV the of and failure are The majority of with elevated HBV and of In patients with cirrhosis or for HBV treatment HBV therapy should with or TAF are the preferred patients with chronic monitoring levels is with for and HBV if levels to or or HBV therapy should if there is evidence of HBV in HBV from for HBV and There are HBV or and approved patients with and more for and review of therapy before initiation of or HBV therapy is with Guidance for Treatment of Patients with HBV and patients should for using the treatment is for patients with HBV treatment is by and levels as the AASLD HBV guidelines for patients are at risk of and with therapy, and monitoring of HBV levels every during treatment and for 3 is in not treatment for patients the AASLD HBV patients with are at risk of with levels should at at the of and during with and for levels or to during treatment or The AASLD 2016 HBV Guidelines of persons at risk for including with HIV persons with and from of Additionally, patients with or HBV levels should for the of to the management of the if there is the to is The is and if this is it should by to of in and has been and the of the quality for by the World Health Organization has led to in Table - at of in with of and with with or HIV with or history of with elevated or with or HBV list is not The of treatment is the of which is by of levels and a in on patients with elevated of HBV and of the for or The of cirrhosis may treatment as is the in HBV are not in patients with or HBV patients with levels may including during treatment of and if the levels treatment with preferred or is of HBV may to which should a on The approved treatment of chronic hepatitis is is the of without in or Treatment as from to the virological The of with does not the of an virological with to of In the study of

IMPORTANCE: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. OBJECTIVE: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. EVIDENCE REVIEW: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). FINDINGS: In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. CONCLUSIONS AND RELEVANCE: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

Potential conflict of interest: Dr. Jonas consults and received grants from Gilead. She received grants from Bristol‐Myers Squibb and Roche. Dr. Chang advises Genentech, Alnylam, and Arbutus. Dr. Terrault consults for Bristol‐Myers Squibb and received grants from Gilead. Dr. Bzowej received grants from Gilead, Synageva, and Ocera. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. This Practice Guideline was approved by the AASLD on August 1, 2015. This Practice Guideline published with accompanying Reviews by Lok et al., Jonas et al., and Brown et al. See Editorial on Page 31 Objectives and Guiding Principles Guiding Principles This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the treatment of chronic hepatitis B (CHB) virus (HBV) infection in adults and children. Unlike previous AASLD practice guidelines, this guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of this guideline will be obtained by reading the applicable portions of the systematic reviews. This guideline focuses on using antiviral therapy in chronic HBV infection and does not address other related and important issues, such as screening, prevention, and surveillance. For broader issues related to diagnosis, surveillance, and prevention as well as treatment in special populations (e.g., liver transplant recipients) that are not addressed by this guideline, the previous AASLD guideline2 and recent World Health Organization (WHO) guideline3 are excellent additional resources. Objectives Guideline developers from the AASLD formulated a list of discrete questions that physicians are faced with in daily practice. These questions were: Should adults with immune active CHB be treated with antiviral therapy to decrease liver‐related complications? Should adults with immune‐tolerant infection be treated with antiviral therapy to decrease liver‐related complications? Should antiviral therapy be discontinued in hepatitis B e antigen (HBeAg)‐positive persons who have developed HBeAg seroconversion on therapy? Should antiviral therapy be discontinued in persons with HBeAg‐negative infection with sustained HBV DNA suppression on therapy? In HBV‐monoinfected persons, does entecavir therapy, when compared to tenofovir therapy, have a different impact on renal and bone health? Is there a benefit to adding a second antiviral agent in persons with persistent low levels of viremia while being treated with either tenofovir or entecavir? Should persons with compensated cirrhosis and low levels of viremia be treated with antiviral agents? Should pregnant women who are hepatitis B surface antigen (HBsAg) positive with high viral load receive antiviral treatment in the third trimester to prevent perinatal transmission of HBV? Should children with HBeAg‐positive CHB be treated with antiviral therapy to decrease liver‐related complications? Target Audience This guideline is intended primarily for health care professionals caring for patients with CHB. Additionally, this guideline may assist policy makers in optimizing the care of individuals living with CHB. Background Burden of Disease Globally, an estimated 240 million persons have CHB with a varying prevalence geographically, highest in Africa and Asia.4 In the United States, the National Health and Nutrition Examination Survey (1999 to 2008) identified approximately 704,000 adults with CHB,5 but with adjustments for hepatitis B infection among foreign‐born persons, the upper estimate of CHB in the United States may be as high as 2.2 million.6 Globally, deaths from cirrhosis and hepatocellular carcinoma (HCC) were estimated at 310,000 and 340,000 per year, respectively.7 To reduce the morbidity and mortality of CHB in the United States and worldwide, there is a need for continued efforts to identify infected individuals through targeted screening, prevent new infections through vaccination, and monitor and treat those at risk for complications of their CHB, including surveillance for HCC.8 Natural History in Adults and Children CHB has been traditionally characterized into four phases (Table 1), reflecting the dynamic relationship between viral replication and evolution and the host immune response. These phases are of variable duration and not every person infected with CHB will evolve through all phases. Given the dynamic nature of CHB infection, serial monitoring of HBV DNA and alanine aminotransferase (ALT) levels is important to characterize the phase of infection. A single ALT and HBV DNA level are insufficient to assign phase of infection and/or need for treatment. Of note, some persons will be in the “gray zones,” that their HBV DNA and ALT levels not into the of ALT and HBV DNA levels and/or of liver to the phase of infection. In this HBV DNA levels are ALT levels are for and for and are of or The duration of this phase is but in those who are infected there is an of from immune‐tolerant to the HBeAg‐positive HBeAg‐positive ALT and HBV DNA levels in with liver characterize this of is among those infected at a The of from the HBeAg‐positive to phases is HBeAg The of seroconversion from HBeAg to to HBeAg is per in children of and and among adults to and per year, CHB In this HBV DNA levels are low or ALT levels are and is Liver but variable reflecting previous liver the HBeAg‐positive persons who HBeAg will to in the CHB of have or to HBeAg HBeAg‐negative immune those who from HBeAg to to have ALT and high HBV DNA and of may have of HBV replication and of hepatitis of of persons HBV in the or and liver and with HBeAg‐negative CHB to have HBV DNA levels those with HBeAg‐positive CHB and are to a of CHB ALT HBV DNA HBeAg Liver phase million and HBeAg‐positive phase or CHB phase or but variable HBeAg‐negative immune phase or CHB infection is by of with of to of persons with CHB will will to levels of HBV DNA are in the in the of persons of or antiviral therapy, risk of and of liver‐related complications is adults with CHB, of cirrhosis is and among those with risk of is and risk of is and of cirrhosis and (Table HBV DNA ALT and HBeAg are among the important of risk of to HBV DNA levels HBeAg and cirrhosis are of A of risk has been in adults with HBV DNA levels a HBV DNA level is with of cirrhosis and and and of of in Africa HBV DNA ALT levels to HBeAg seroconversion Development of HBeAg‐negative CHB of cirrhosis HBV DNA ALT to HBeAg seroconversion Development of HBeAg‐negative CHB viral infections and viral infections and and of CHB The of persons with CHB a and with special on risk for and of HBV infection and liver of liver and of HBV and for with hepatitis virus hepatitis virus or virus in those at risk (Table to the nature of CHB, the of high HBV DNA level at a single in is and monitoring of is to need for antiviral The upper of for ALT on are from all including those with liver Evaluation of Examination patients of cirrhosis and risk of including HBV DNA to need for or or patients to other of chronic liver liver HBV in those who have not Liver of the of liver is important in antiviral therapy and need for surveillance. Liver an of the of and other of liver and may be for persons who for treatment. liver is as the to the of and to are of hepatitis B may to of by and different for and on ALT levels have been of such as aminotransferase and have in persons with or on the but in and may be in The of antiviral treatment are to decrease the morbidity and mortality related to CHB. The of a sustained suppression of HBV replication has been with of of HBeAg with or of and in liver the was in treatment of CHB, that of DNA the of in the of in persons with of infection, a risk for of infection. an may be by and sustained HBV DNA suppression and a by of including the The is not an are approved for the treatment of adults with CHB in the United States and approved for the treatment of children with CHB (Table are with therapy with all have an excellent a of persons with CHB, including those with cirrhosis and transplant The in for are For persons with the treatment is For persons with treatment of HBV to be with therapy that HBV have and in Adults and Children in in Potential on million in adults and in children to every monitoring for and complications daily daily to levels daily B and levels or to levels daily daily renal at at risk for renal and at bone at and treatment in persons with of or for levels daily daily B at at risk for renal and at bone at and treatment in persons with of or for levels need to be in persons with renal is not approved for children with CHB, but is approved for treatment of chronic hepatitis may using this for children with chronic The duration of treatment in adults is in adults is daily or or in children and at and For children and at the entecavir and and are to the of therapy (Table are on therapy and therapy The of sustained is but this is with of in Adults CHB and Disease HBV DNA HBeAg HBeAg seroconversion 31 HBV DNA of of of DNA for for entecavir and DNA for for entecavir and by of Guideline Development The questions a for by the guidelines are in CHB therapy treatment of CHB, adults therapy treatment of HBeAg‐positive chronic with HBeAg seroconversion on therapy antiviral therapy antiviral therapy of HBeAg‐negative chronic with viral suppression on antiviral therapy antiviral therapy antiviral therapy of CHB on treatment with therapy bone health CHB on treatment with therapy with persistent viremia therapy or therapy HBV of HBeAg CHB with with HBV DNA therapy treatment women with CHB therapy in third trimester treatment CHB in the HBeAg‐positive CHB, therapy treatment HBeAg of A and the of A of AASLD with an with in systematic reviews to the and the systematic the (Table In this the of in is as or low on the of and risk of and The recommendations on the of of and and and are as to patients with or to the of patients and are with the of are to recommendations to to of the questions are as an to this For the questions with and are The the of Study of of when of when (e.g., (e.g., the low of the of a Recommendation of of and and and of the of Recommendation in this the of and a Health care receive the of The be as a policy in The of in this the of but Health care to patients a that is with their using and is a need for and of of CHB The AASLD antiviral therapy for adults with CHB or HBeAg to decrease the risk of liver‐related of of The AASLD or tenofovir as therapy for adults with CHB. of of CHB is by an of ALT or of HBV DNA or The for ALT in adults is for and for is insufficient for or of ALT other ALT The to treat persons with ALT the but of of liver by or is for persons with CHB and cirrhosis HBV DNA of ALT in the to treat persons with CHB but ALT and HBV DNA is with of of treatment of and may to treatment is a risk for of for treatment of liver of HBV DNA be with and the be as a but not for treatment. of antiviral to of therapy in risk in liver‐related in and entecavir as the important was the of with that need to be in between and tenofovir for therapy of treatment (Table is in persons with and of is not in this A therapy with or of antiviral that is in is (Table HBV A and B are to HBeAg and with is for For persons treated with duration is in and is This treatment duration HBeAg seroconversion of and sustained HBV DNA suppression in of persons who HBeAg to The of and has not of or and is not of therapy for therapy is variable and by HBeAg duration of HBV DNA and of in persons with Evaluation for of using or liver is in treatment including duration of with does not the risk of and surveillance for in persons who are at Background CHB is a dynamic characterized by variable of immune that in the development of liver and liver‐related in a of ALT and HBV DNA levels are of risk of liver a of infection, HBV and HBV and The of HBV therapy is to prevent liver‐related morbidity and in the phases of infection positive and of liver and/or and HBV DNA levels with a risk of liver and and The is in A of were to treatment and of or were and were a of provided in persons with and provided in persons with antiviral compared to treatment and compared therapy to treatment. A to antiviral was not to the of per The of was for low to low to of per was per For the of was and The of the treatment in liver‐related and and of risk and among to of the of the therapy to was with risk in cirrhosis in risk and a risk in and and a risk in the of persons with antiviral therapy risk of and liver but not in mortality In by of therapy, and of cirrhosis and but were with of and The for treatment in a person with is the of liver or as by ALT levels or on and/or active HBV of treatment in adults for ALT to ALT and ALT for is that the ALT levels of adults are for and for using ALT for the to treatment of adults with ALT of the for and for is the ALT in the The HBV DNA levels to are on of with from that the risk of liver‐related complications with HBV DNA levels In systematic liver‐related in persons antiviral therapy by HBV DNA level and in Liver are not to treatment of the of previous to treatment is important in treatment duration of therapy, and does not the ALT and HBV DNA at treatment be A high on and on are with of the with treatment seroconversion and HBV DNA such as may be in cirrhosis have high but are in of or and high ALT levels are with and this to be into in are to risk benefit for persons with ALT and HBV DNA (e.g., for HBeAg positive and for HBeAg who are in the “gray for ALT and HBV DNA for treatment to the of of in treatment are is a need for treatment that the HBV to of Adults CHB The AASLD antiviral therapy for adults with immune‐tolerant CHB. of of be by ALT levels for and for women as The AASLD that ALT levels be at every for adults with immune‐tolerant CHB to monitor for to or CHB. of low of The AASLD antiviral therapy in the of adults of with ALT and HBV DNA and liver or of low of or on liver is a to of antiviral therapy, other of liver are Background Natural have a between HBV DNA levels and the development of and of ALT HBV and HBeAg in This the of adults in the immune‐tolerant phase of infection benefit from antiviral Of note, as In using ALT of for and for and is in the of HBeAg‐positive adults with high HBV DNA In persons who their infection at or in the of from immune‐tolerant to phases is is with of in HBeAg‐positive persons with ALT and The is in of in immune‐tolerant adults with ALT ALT for were with treatment duration of for or for with of HBeAg and seroconversion as the antiviral therapy to treatment were the this The were of different antiviral to antiviral therapy in a of HBeAg and seroconversion of by treatment and all that different from The were and the to persons with ALT were low to low are that antiviral therapy is in of and liver‐related in persons with immune‐tolerant CHB. treatment duration for of HBeAg but not and among including persons with ALT The persons with HBeAg‐positive immune active a for antiviral Given the of of benefit to those with ALT of immune‐tolerant the of antiviral therapy, including antiviral and development of Additionally, there are to a for treatment of immune‐tolerant persons with of the of persons with ALT levels and high HBV DNA levels have and/or on liver the of with for adults with an immune‐tolerant but or antiviral therapy is but the of this is of therapy and are to and of antiviral therapy in adults in the immune‐tolerant phase of CHB, in persons with of of HBeAg to on The AASLD that HBeAg‐positive adults cirrhosis with CHB who to on therapy a of treatment of of The of therapy treatment for at of ALT levels and HBV DNA is not a duration of reduce of an is to treat treatment duration and of treatment of and for health risk for liver and of continued antiviral therapy, with and and for with treatment and and These for HBeAg‐positive adults and with cirrhosis who to on who antiviral therapy be every for at for ALT and The AASLD antiviral therapy for HBeAg‐positive adults with cirrhosis with CHB who to on therapy, on for and there is a for treatment of of with cirrhosis who antiviral therapy be (e.g., for every for ALT and may be in persons who have of there is insufficient to treatment for such Background HBeAg and sustained HBV DNA suppression are of antiviral therapy in HBeAg‐positive persons, those of or seroconversion is the of immune of antiviral therapy, persons with HBeAg‐positive immune active who are treated with antiviral therapy may be to treatment of the of HBeAg treatment with antiviral therapy seroconversion is may be an but may not be for all persons to of and need for is health such as or are different in persons who HBeAg seroconversion compared to those who continued antiviral therapy and is the important of or among HBeAg‐positive persons who antiviral therapy compared to those who continued HBeAg compared continued therapy to a of and of ALT and HBeAg that persons who treatment a of viremia and of ALT of the persons who continued treatment either The second a of ALT of in those who in those who continued antiviral The of HBV DNA was in persons who in those who and that of HBeAg was duration of therapy from HBeAg seroconversion to antiviral treatment was to be and In other of HBeAg seroconversion for entecavir was at and for was at The for antiviral therapy is on the of of therapy in of and with the and with antiviral of antiviral therapy may of and risk of liver in with Additionally, the risk of is in persons who are positive those who were and the risk of cirrhosis is in persons with persistent HBeAg A of has been to reduce the risk of HBeAg the duration of HBeAg seroconversion is for HBeAg‐positive persons who to on health such as or in to the duration of of antiviral therapy in persons cirrhosis and impact of antiviral therapy in persons with of in CHB The AASLD antiviral therapy for adults with HBeAg‐negative CHB, there is a for treatment of of A to therapy for HBeAg‐negative adults cirrhosis of and for health risk for liver and of continued antiviral therapy, with and and for with treatment and and in persons with cirrhosis is not to the for and are may be in persons who have of there is insufficient to treatment for such who antiviral therapy be every for at for ALT and therapy is not for persons cirrhosis who are HBeAg with ALT and viremia chronic hepatitis Background The are in HBV DNA not or viral DNA into the host HBV viremia treatment virus suppression therapy, in some with hepatitis and/or In this antiviral therapy is A previous AASLD hepatitis B practice guideline antiviral therapy for HBeAg‐negative persons was and The is in important such as and among HBeAg‐negative persons who compared to those who continued antiviral were duration of therapy antiviral therapy in HBeAg‐negative an compared treatment duration and were with of viremia in persons treatment viremia in persons with or of four the of treatment in HBeAg‐negative persons with duration of therapy or including and These viremia to level in and ALT in approximately third to of the was in of persons who therapy at of therapy in and in of of therapy in there was in between adults with and in of with cirrhosis in In a from of persons with CHB HBeAg who discontinued therapy from a hepatitis B with the of at 1, and was and there was in the of between persons with and persons with cirrhosis of that virus suppression and ALT may be sustained in of the HBeAg‐negative persons with treatment duration or the of treatment on morbidity and mortality with persistent for and in persons with for treatment of for and Given the health with and antiviral therapy, with duration of are to antiviral therapy be in persons with and treatment for patients on therapy, such as adding or to therapy, are to identify for treatment including levels in the United and and Disease in on Recommendation The AASLD between entecavir and tenofovir of renal and bone of of The not in renal or bone between persons treated with tenofovir or renal such as renal or have been in In persons on renal including and be treatment and (e.g., at and or high risk for renal In the of other risk for there is insufficient for or monitoring of bone in persons on In of renal and/or tenofovir be discontinued and with an with for previous of be on renal and as by Background and tenofovir are approved as for CHB. tenofovir therapy has been with and chronic with and and on from tenofovir therapy in persons has been with bone and there was risk for or with tenofovir therapy in persons in a systematic and of and have been in persons on HBV infection and liver to the of tenofovir a compared to is the for The of renal and bone for to of treatment was low in a recent with and in bone between and from identified a need for in of persons for renal an approximately a and for The of with approved HBV was in of persons with cirrhosis treated with and risk of was with the of for Liver including and The is in The of tenofovir and entecavir was compared in with of per treatment The of adults with cirrhosis in or of tenofovir or entecavir The second of adults on on in renal and in treatment duration was in In the in and/or between the treatment a in of for tenofovir entecavir a in bone in and adults with an treatment duration of additional in of and in of treated with with an additional of renal in A recent of persons with of low risk for renal and bone was a risk for persons on therapy for the risk was low The duration of in of the with to to in low to low of in the for of renal in persons that persons on tenofovir have renal at with treatment duration and are to renal and bone with therapy, in to and to prevent and of on The AASLD that persons with persistent viremia on entecavir or tenofovir of of of The AASLD of in persons with on entecavir or tenofovir either to antiviral with high to or a second antiviral that of of patients is in those with persistent viremia on antiviral viremia has traditionally been as HBV DNA of treatment. This was by of in and an of antiviral therapy with of antiviral and of the of entecavir and persistent viremia is as a in the of HBV DNA and/or to HBV DNA level of is insufficient to for adding a second or to in of in this may not be viral levels are to is by an in HBV DNA by compared to or HBV DNA in persons on therapy with levels be obtained a therapy may assist with A a for to antiviral with high to or adding a second antiviral with a (Table is insufficient to the risk of viral is to be with antiviral therapy compared to the of HBV DNA monitoring has not been monitoring of HBV DNA levels every HBV DNA is and every for of persistent viremia and For persons on treatment with other tenofovir or viral a to antiviral with high to or the of a second antiviral with a (Table for of tenofovir tenofovir entecavir tenofovir tenofovir and entecavir Background all persons viral suppression on entecavir or tenofovir therapy of those treated with of HBeAg‐positive and of HBeAg‐negative viral For those treated with viral suppression were for HBeAg‐positive persons and for HBeAg‐negative For persons on therapy who to an HBV DNA level of therapy, but not for is as to a of therapy is The of adding on an additional antiviral therapy to an to antiviral has not been In on antiviral treatment is with viral and a of and was of to continued among persons with persistent the of was low the of persons with persistent viremia who continued entecavir or tenofovir compared to persons who to with high to or a second antiviral with to viral of persons on with persistent viremia viral or on there was support in of either to a or adding a second antiviral with a In a of persons with entecavir treated with tenofovir or tenofovir and the of viral suppression at was and in the In of persons with treated with tenofovir or tenofovir and entecavir for there was in the of viral suppression between the are of insufficient duration to therapy in of risk for with treatment are to care for persons with persistent viremia or on antiviral is to the health of and adding on antiviral need that a in antiviral therapy, and the of different of Adults and The AASLD that adults with compensated cirrhosis and low levels of viremia be treated with antiviral therapy to reduce the risk of of ALT of of and entecavir are of their and risk of with a low to not be the of to is not in persons with compensated but are treatment is not to persons with compensated cirrhosis and low levels of be for a in HBV DNA and/or be either The ALT level in persons is or the ALT levels the of other for ALT is is a for antiviral does not an of treatment. therapy were monitoring every for at for of viral that to with compensated cirrhosis and high HBV DNA levels are treated per recommendations for HBeAg‐positive and CHB with does not the risk of and surveillance for The AASLD that adults with cirrhosis be treated with antiviral therapy of HBV DNA HBeAg or ALT level to decrease risk of liver‐related of of and tenofovir are is in persons with cirrhosis to for liver is in has been with some and persons with cirrhosis may be at of and is with does not the risk of and surveillance for Background The of HBV treatment is to prevent and liver‐related complications through of sustained suppression of In those with and/or on and/or ALT in with HBV DNA the risk of liver‐related complications is highest and the for treatment be persons with cirrhosis but ALT levels and low levels of viremia are at risk is and have that of hepatitis B in viral load to in with an in at a of per in persons with with a viral load between and to be at the highest there is for using antiviral therapy in persons with cirrhosis and low levels of HBV that and liver‐related or a In of persons with cirrhosis HBV DNA and HBeAg at the developed the other in risk was among patients those with HBV DNA

Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (P less than 0.001) and 28 percent in those treated with 1 million units (P less than 0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

Sedentary behavior and physical inactivity are among the leading modifiable risk factors worldwide for cardiovascular disease and all-cause mortality. The promotion of physical activity and exercise training (ET) leading to improved levels of cardiorespiratory fitness is needed in all age groups, race, and ethnicities and both sexes to prevent many chronic diseases, especially cardiovascular disease. In this state-of-the-art review, we discuss the negative impact of sedentary behavior and physical inactivity, as well as the beneficial effects of physical activity /ET and cardiorespiratory fitness for the prevention of chronic noncommunicable diseases, including cardiovascular disease. We review the prognostic utility of cardiorespiratory fitness compared with obesity and the metabolic syndrome, as well as the increase of physical activity /ET for patients with heart failure as a therapeutic strategy, and ET dosing. Greater efforts at preventing sedentary behavior and physical inactivity while promoting physical activity, ET, and cardiorespiratory fitness are needed throughout the healthcare system worldwide and particularly in the United States in which the burden of cardiometabolic diseases remains extremely high.

Cardiovascular diseases (CVDs) are the major causes of mortality in persons with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. Hypertension is approximately twice as frequent in patients with diabetes compared with patients without the disease. Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons. Furthermore, up to 75% of CVD in diabetes may be attributable to hypertension, leading to recommendations for more aggressive treatment (ie, reducing blood pressure to <130/85 mm Hg) in persons with coexistent diabetes and hypertension. Other important risk factors for CVD in these patients include the following: obesity, atherosclerosis, dyslipidemia, microalbuminuria, endothelial dysfunction, platelet hyperaggregability, coagulation abnormalities, and "diabetic cardiomyopathy." The cardiomyopathy associated with diabetes is a unique myopathic state that appears to be independent of macrovascular/microvascular disease and contributes significantly to CVD morbidity and mortality in diabetic patients, especially those with coexistent hypertension. This update reviews the current knowledge regarding these risk factors and their treatment, with special emphasis on the cardiometabolic syndrome, hypertension, microalbuminuria, and diabetic cardiomyopathy. This update also examines the role of the renin-angiotensin system in the increased risk for CVD in diabetic patients and the impact of interrupting this system on the development of clinical diabetes as well as CVD.

CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials. OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS). DESIGN, SETTING, AND PARTICIPANTS: Randomized, open label, blinded end point study of 22 576 hypertensive CAD patients aged 50 years or older, which was conducted September 1997 to February 2003 at 862 sites in 14 countries. INTERVENTIONS: Patients were randomly assigned to either CAS (verapamil sustained release) or NCAS (atenolol). Strategies specified dose and additional drug regimens. Trandolapril and/or hydrochlorothiazide was administered to achieve blood pressure goals according to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) of less than 140 mm Hg (systolic) and less than 90 mm Hg (diastolic); and less than 130 mm Hg (systolic) and less than 85 mm Hg (diastolic) if diabetes or renal impairment was present. Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment. MAIN OUTCOME MEASURES: Primary: first occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months. RESULTS: At 24 months, in the CAS group, 6391 patients (81.5%) were taking verapamil sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide. In the NCAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trandolapril. After a follow-up of 61 835 patient-years (mean, 2.7 years per patient), 2269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in CAS and 10.17% in NCAS; relative risk [RR], 0.98; 95% confidence interval [CI], 0.90-1.06). Two-year blood pressure control was similar between groups. The JNC VI blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of CAS and 64.0% (systolic) and 88.1% (diastolic) of NCAS patients. A total of 71.7% of CAS and 70.7% of NCAS patients achieved a systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg. CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.

Stress response elements, which mediate induction of the mouse heme oxygenase-1 (HO-1) gene by several agents, resemble the binding site for the activator protein-1 (Jun/Fos), Maf, and Cap'n'Collar/basic leucine zipper (CNC-bZIP) families of proteins. In L929 fibroblasts, significant activation of an HO-1 enhancer-reporter fusion gene was observed only with the CNC-bZIP class of proteins with Nrf2 exhibiting the highest level of trans-activation, between 25- and 30-fold. To further examine the role of this factor in HO-1 gene regulation, a dominant-negative mutant, Nrf2M, was generated and conditionally expressed in L929 cells. The mutant protein was detected in cytoplasmic and nuclear fractions but did not affect cell growth. Under conditions of Nrf2M overexpression, HO-1 mRNA accumulation in response to heme, cadmium, zinc, arsenite, and tert-butylhydroquinone was inhibited by 85-95%. In contrast, overexpression of a dominant-negative mutant of c-Jun decreased L929 cell growth but did not inhibit HO-1 gene activation. Nrf2 does not homodimerize, but CNC-bZIP.small Maf protein heterodimers and Nrf2. Jun protein complexes are proposed to function as trans-activators. Co-expression of Jun proteins or p18, however, had no significant affect or inhibited Nrf2-mediated trans-activation. Taken together, these results implicate Nrf2 in the induction of the HO-1 gene but suggest that the Nrf2 partner in this function is a factor other than p18 or Jun proteins.

BACKGROUND AND METHODS: Although the nucleoside analogue lamivudine has shown promise in patients with chronic hepatitis B, long-term data on patients from the United States are lacking. We randomly assigned previously untreated patients with chronic hepatitis B to receive either 100 mg of oral lamivudine or placebo daily for 52 weeks. We then followed them for an additional 16 weeks to evaluate post-treatment safety and the durability of responses. The primary end point with respect to efficacy was a reduction of at least 2 points in the score on the Histologic Activity Index. On this scale, scores can range from 0 (normal) to 22 (most severe abnormalities). RESULTS: Of the 143 randomized patients, 137 were included in the efficacy analysis: 66 in the lamivudine group and 71 in the placebo group. The other six patients were excluded at the base-line visit because of the absence of a documented history of hepatitis B surface antigen for at least six months. After 52 weeks of treatment, lamivudine recipients were more likely than placebo recipients to have a histologic response (52 percent vs. 23 percent, P<0.001), loss of hepatitis B e antigen (HBeAg) in serum (32 percent vs. 11 percent, P=0.003), sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable levels (44 percent vs. 16 percent, P<0.001), and sustained normalization of serum alanine aminotransferase levels (41 percent vs. 7 percent, P<0.001), and they were less likely to have increased hepatic fibrosis (5 percent vs. 20 percent, P=0.01). Lamivudine recipients were also more likely to undergo HBeAg seroconversion, defined as the loss of HBeAg, undetectable levels of serum HBV DNA, and the appearance of antibodies against HBeAg (17 percent vs. 6 percent, P=0.04). HBeAg responses persisted in most patients for 16 weeks after the discontinuation of treatment. Lamivudine was well tolerated. Self-limited post-treatment elevations in serum alanine aminotransferase were more common in lamivudine recipients: 25 percent had serum alanine aminotransferase levels that were at least three times base-line levels, as compared with 8 percent of placebo recipients (P=0.01). The clinical condition of all patients remained stable during the study. CONCLUSIONS: In U.S. patients with previously untreated chronic hepatitis B, one year of lamivudine therapy had favorable effects on histologic, virologic, and biochemical features of the disease and was well tolerated. HBeAg responses were generally sustained after treatment.

The distinction between bactericidal and bacteriostatic agents appears to be clear according to the in vitro definition, but this only applies under strict laboratory conditions and is inconsistent for a particular agent against all bacteria. The distinction is more arbitrary when agents are categorized in clinical situations. The supposed superiority of bactericidal agents over bacteriostatic agents is of little relevance when treating the vast majority of infections with gram-positive bacteria, particularly in patients with uncomplicated infections and noncompromised immune systems. Bacteriostatic agents (e.g., chloramphenicol, clindamycin, and linezolid) have been effectively used for treatment of endocarditis, meningitis, and osteomyelitis--indications that are often considered to require bactericidal activity. Although bacteriostatic/bactericidal data may provide valuable information on the potential action of antibacterial agents in vitro, it is necessary to combine this information with pharmacokinetic and pharmacodynamic data to provide more meaningful prediction of efficacy in vivo. The ultimate guide to treatment of any infection must be clinical outcome.

IMPORTANCE: Evidence about the efficacy of laparoscopic resection of rectal cancer is incomplete, particularly for patients with more advanced-stage disease. OBJECTIVE: To determine whether laparoscopic resection is noninferior to open resection, as determined by gross pathologic and histologic evaluation of the resected proctectomy specimen. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, balanced, noninferiority, randomized trial enrolled patients between October 2008 and September 2013. The trial was conducted by credentialed surgeons from 35 institutions in the United States and Canada. A total of 486 patients with clinical stage II or III rectal cancer within 12 cm of the anal verge were randomized after completion of neoadjuvant therapy to laparoscopic or open resection. INTERVENTIONS: Standard laparoscopic and open approaches were performed by the credentialed surgeons. MAIN OUTCOMES AND MEASURES: The primary outcome assessing efficacy was a composite of circumferential radial margin greater than 1 mm, distal margin without tumor, and completeness of total mesorectal excision. A 6% noninferiority margin was chosen according to clinical relevance estimation. RESULTS: Two hundred forty patients with laparoscopic resection and 222 with open resection were evaluable for analysis of the 486 enrolled. Successful resection occurred in 81.7% of laparoscopic resection cases (95% CI, 76.8%-86.6%) and 86.9% of open resection cases (95% CI, 82.5%-91.4%) and did not support noninferiority (difference, -5.3%; 1-sided 95% CI, -10.8% to ∞; P for noninferiority = .41). Patients underwent low anterior resection (76.7%) or abdominoperineal resection (23.3%). Conversion to open resection occurred in 11.3% of patients. Operative time was significantly longer for laparoscopic resection (mean, 266.2 vs 220.6 minutes; mean difference, 45.5 minutes; 95% CI, 27.7-63.4; P < .001). Length of stay (7.3 vs 7.0 days; mean difference, 0.3 days; 95% CI, -0.6 to 1.1), readmission within 30 days (3.3% vs 4.1%; difference, -0.7%; 95% CI, -4.2% to 2.7%), and severe complications (22.5% vs 22.1%; difference, 0.4%; 95% CI, -4.2% to 2.7%) did not differ significantly. Quality of the total mesorectal excision specimen in 462 operated and analyzed surgeries was complete (77%) and nearly complete (16.5%) in 93.5% of the cases. Negative circumferential radial margin was observed in 90% of the overall group (87.9% laparoscopic resection and 92.3% open resection; P = .11). Distal margin result was negative in more than 98% of patients irrespective of type of surgery (P = .91). CONCLUSIONS AND RELEVANCE: Among patients with stage II or III rectal cancer, the use of laparoscopic resection compared with open resection failed to meet the criterion for noninferiority for pathologic outcomes. Pending clinical oncologic outcomes, the findings do not support the use of laparoscopic resection in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00726622.

The transcription factor Nrf2, which normally exists in an inactive state as a consequence of binding to a cytoskeleton-associated protein Keap1, can be activated by redox-dependent stimuli. Alteration of the Nrf2-Keap1 interaction enables Nrf2 to translocate to the nucleus, bind to the antioxidant-responsive element (ARE) and initiate the transcription of genes coding for detoxifying enzymes and cytoprotective proteins. This response is also triggered by a class of electrophilic compounds including polyphenols and plant-derived constituents. Recently, the natural antioxidants curcumin and caffeic acid phenethyl ester (CAPE) have been identified as potent inducers of haem oxygenase-1 (HO-1), a redox-sensitive inducible protein that provides protection against various forms of stress. Here, we show that in renal epithelial cells both curcumin and CAPE stimulate the expression of Nrf2 in a concentration- and time-dependent manner. This effect was associated with a significant increase in HO-1 protein expression and haem oxygenase activity. From several lines of investigation we also report that curcumin (and, by inference, CAPE) stimulates ho-1 gene activity by promoting inactivation of the Nrf2-Keap1 complex, leading to increased Nrf2 binding to the resident ho-1 AREs. Moreover, using antibodies and specific inhibitors of the mitogen-activated protein kinase (MAPK) pathways, we provide data implicating p38 MAPK in curcumin-mediated ho-1 induction. Taken together, these results demonstrate that induction of HO-1 by curcumin and CAPE requires the activation of the Nrf2/ARE pathway.

OBJECTIVE: To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, double-blind, placebo-controlled, parallel-group trial randomized 533 subjects (1:1:1) to once-daily liraglutide (1.2 or 1.8 mg) or liraglutide placebo in combination with metformin (1 g twice daily) and rosiglitazone (4 mg twice daily). Subjects had type 2 diabetes, A1C 7-11% (previous oral antidiabetes drug [OAD] monotherapy >or=3 months) or 7-10% (previous OAD combination therapy >or=3 months), and BMI <or=45 kg/m(2). RESULTS: Mean A1C values decreased significantly more in the liraglutide groups versus placebo (mean +/- SE -1.5 +/- 0.1% for both 1.2 and 1.8 mg liraglutide and -0.5 +/- 0.1% for placebo). Fasting plasma glucose decreased by 40, 44, and 8 mg/dl for 1.2 and 1.8 mg and placebo, respectively, and 90-min postprandial glucose decreased by 47, 49, and 14 mg/dl, respectively (P < 0.001 for all liraglutide groups vs. placebo). Dose-dependent weight loss occurred with 1.2 and 1.8 mg liraglutide (1.0 +/- 0.3 and 2.0 +/- 0.3 kg, respectively) (P < 0.0001) compared with weight gain with placebo (0.6 +/- 0.3 kg). Systolic blood pressure decreased by 6.7, 5.6, and 1.1 mmHg with 1.2 and 1.8 mg liraglutide and placebo, respectively. Significant increases in C-peptide and homeostasis model assessment of beta-cell function and significant decreases in the proinsulin-to-insulin ratio occurred with liraglutide versus placebo. Minor hypoglycemia occurred more frequently with liraglutide, but there was no major hypoglycemia. Gastrointestinal adverse events were more common with liraglutide, but most occurred early and were transient. CONCLUSIONS: Liraglutide combined with metformin and a thiazolidinedione is a well-tolerated combination therapy for type 2 diabetes, providing significant improvements in glycemic control.

BACKGROUND: Better treatments for chronic hepatitis B are needed. Lamivudine, the (-)enantiomer of 3'-thiacytidine, is a potent inhibitor of hepatitis B virus (HBV). METHODS: In a double-blind trial, we randomly assigned 32 patients with chronic hepatitis B (including 17 who had no response to earlier treatment with interferon) to receive 25, 100, or 300 mg of oral lamivudine daily for 12 weeks. The patients were then followed for 24 additional weeks. All the patients had hepatitis B antigen in serum. RESULTS: Levels of HBV DNA became undetectable (< or = 1.5 pg per milliliter) in 70 percent of the patients who received the 25-mg dose of lamivudine and 100 percent of those treated with the 100-mg or 300-mg dose. In most patients, HBV DNA reappeared after therapy was completed; however, six patients (19 percent), including five who had not responded to interferon, had sustained suppression of HBV DNA accompanied by normalization of alanine aminotransferase levels. Hepatitis B e antigen disappeared in four of these six patients (12 percent), three of whom had had no response to interferon. Levels of HBV DNA fell in all patients, including those who had had high levels at base line or normal alanine aminotransferase levels at base line, but sustained responses were more likely in patients with initially low HBV DNA levels and high alanine aminotransferase levels. During and after therapy, alanine aminotransferase levels at least doubled in five patients (50 percent) given the 25-mg dose and eight patients (36 percent) given the 100-mg or 300-mg dose. Minor adverse events occurred that were not related to the dose, as did transient, asymptomatic elevations of amylase, lipase, and creatine kinase levels. CONCLUSIONS: In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.

BACKGROUND: As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS: We conducted a phase 3, open-label study involving both previously treated and previously untreated patients infected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in a 1:1:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 267 patients who received treatment, 78% had HCV genotype 1, 4% genotype 2, 15% genotype 3, 3% genotype 4, and less than 1% genotype 6; no patients had genotype 5. Overall rates of sustained virologic response were 83% (95% confidence interval [CI], 74 to 90) among patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) among those who received 24 weeks of sofosbuvir-velpatasvir. Post hoc analysis did not detect any significant differences in rates of sustained virologic response among the three study groups. Serious adverse events occurred in 19% of patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who received 24 weeks of sofosbuvir-velpatasvir. The most common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the patients receiving ribavirin. CONCLUSIONS: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. (Funded by Gilead Sciences; ASTRAL-4 ClinicalTrials.gov number, NCT02201901.).

Aspergillosis comprises a variety of manifestations of infection. These guidelines are directed to 3 principal entities: invasive aspergillosis, involving several organ systems (particularly pulmonary disease); pulmonary aspergilloma; and allergic bronchopulmonary aspergillosis. The recommendations are distilled in this summary, but the reader is encouraged to review the more extensive discussions in subsequent sections, which show the strength of the recommendations and the quality of the evidence, and the original publications cited in detail. Invasive aspergillosis. Because it is highly lethal in the immunocompromised host, even in the face of therapy, work-up must be prompt and aggressive, and therapy may need to be initiated upon suspicion of the diagnosis, without definitive proof (BIII). Intravenous therapy should be used initially in rapidly progressing disease (BIII). The largest therapeutic experience is with amphotericin B deoxycholate, which should be given at maximum tolerated doses (e.g., 1–1.5 mg/kg/d) and should be continued, despite modest increases in serum creatinine levels (BIII). Lipid formulations of amphotericin are indicated for the patient who has impaired renal function or who develops nephrotoxicity while receiving deoxycholate amphotericin (AII). Oral itraconazole is an alternative for patients who can take oral medication, are likely to be adherent, can be demonstrated (by serum level monitoring) to absorb the drug, and lack the potential for interaction with other drugs (BII). Oral itraconazole is attractive for continuing therapy in the patient who responds to initial iv therapy (CIII). Therapy should be prolonged beyond resolution of disease and reversible underlying predispositions (BIII). Adjunctive therapy (particularly surgery and combination chemotherapy, also immunotherapy), may be useful in certain situations (CIII). Aspergilloma. The optimal treatment strategy for aspergilloma is unknown. Therapy is predominantly directed at preventing life-threatening hemoptysis. Surgical removal of aspergilloma is definitive treatment, but because of significant morbidity and mortality it should be reserved for high-risk patients such as those with episodes of life-threatening hemoptysis, and considered for patients with underlying sarcoidosis, immunocompromised patients, and those with increasing Aspergillus-specific IgG titers (CIII). Surgical candidates would need to have adequate pulmonary function to undergo the operation. Bronchial artery embolization rarely produces a permanent success, but may be useful as a temporizing procedure in patients with life-threatening hemoptysis. Endobronchial and intracavitary instillation of antifungals or oral itraconazole may be useful for this condition. Since the majority of aspergillomas do not cause life-threatening hemoptysis, the morbidity and cost of treatment must be weighed against the clinical benefit. Allergic bronchopulmonary aspergillosis (APBA). Although no well-designed studies have been carried out, the available data support the use of corticosteroids for acute exacerbations of ABPA (AII). Neither the optimal corticosteroid dose nor the duration of therapy has been standardized, but limited data suggest the starting dose should be ∼0.5 mg/kg/d of prednisone. The decision to taper corticosteroids should be made on an individual basis, depending on the clinical course (BIII). The available data suggest that clinical symptoms alone are inadequate to make such decisions, since significant lung damage may occur in asymptomatic patients. Increasing serum IgE levels, new or worsening infiltrate on chest radiograph, and worsening spirometry suggest that corticosteroids should be used (BII). Multiple asthmatic exacerbations in a patient with ABPA suggest that chronic corticosteroid therapy should be used (BIII). Itraconazole appears useful as a corticosteroid sparing agent (BII). Although the frequency of these diseases is on the rise, there is a paucity of randomized comparative trials involving these entities; therefore, the recommendations represent a compromise and consensus among students of these diseases (i.e., the authors). They have synthesized the recommendations from published and personal experience, including case series, open trials, and any comparative trials, as indicated. Aspergillus species are saprophytic molds found worldwide. Diseases caused by Aspergillus species are most commonly caused by Aspergillus fumigatus, with Aspergillus flavus the second most frequently isolated pathogen. Other species reported to cause disease include Aspergillus amstelodami, Aspergillus avenaceus, Aspergillus candidus, Aspergillus carneus, Aspergillus caesiellus, Aspergillus clavatus, Aspergillus glaucus, Aspergillus granulosus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus quadrilineatus, Aspergillus restrictus, Aspergillus sydowi, Aspergillus terreus, Aspergillus ustus, and Aspergillus versicolor. The frequency and relative importance of these infections are on the rise in all developed countries, which is possibly related to increased numbers of immunocompromised patients, owing to improved survival from AIDS, malignancies and more intensive cytotoxic therapy, more transplantation (with immunosuppression) for organ dysfunctions, and better therapy and prophylaxis for candidal infections. These guidelines are drafted to ensure appropriate and successful therapy for 3 main diseases caused by Aspergillus species. They include invasive aspergillosis, ABPA, and aspergilloma. The guidelines proposed initially are general and are followed by modifications for individual clinical settings. The guidelines are based on scientific publications and peer-reviewed information (this documentation is provided), and are largely concerned with therapy. The guidelines are not intended to be a comprehensive treatise on pathogenesis or diagnosis. The categories of ranking of the strength of the recommendation and the quality of the evidence are given in tables 1 and 2. Guidelines for prophylaxis and empirical therapy for invasive aspergillosis in neutropenic hosts have recently been published [1] and will not be discussed here. Categories reflecting the strength of each recommendation for or against the use of therapy for diseases caused by Aspergillus species. Categories indicating the quality of evidence for recommendations for antifungal therapy in diseases caused by Aspergillus species. General and specific commentary on antifungal drugs has been provided in a previous guideline in this series. The drugs available to treat aspergillosis presently include amphotericin B in deoxycholate [2–4], a familiar drug with 40 years' clinical experience; 3 lipid-based preparations of amphotericin B [5–12]; and itraconazole, an oral and iv triazole [13–18]. In general, the largest databases for therapy in aspergillosis concern amphotericin B deoxycholate and various surgical modalities. There is thus some concern about the efficacy of the newer in patients with rapidly invasive Itraconazole has drug which are in patients at of aspergillosis, because such patients are receiving other drugs for a variety of These patients also have as a of these therefore, oral itraconazole is serum should be to ensure adequate (BII). should be given to the oral of itraconazole in such patients, because is to that with itraconazole iv has been but there is information available about that any drug used for invasive disease be given at for 1–1.5 mg/kg/d of amphotericin B deoxycholate, mg/kg/d of formulations of and of itraconazole (BIII). in serum creatinine level with amphotericin B deoxycholate is and with amphotericin use are to the dose because of a modest of and have against Aspergillus species and are or clinical oral triazole and 3 and are also in of clinical Invasive aspergillosis is a that patients with or cytotoxic chemotherapy, corticosteroid therapy, or organ or or in patients at and prompt of antifungal therapy may be for patient survival (BIII). The are the most of invasive disease it in frequency in some The is the most of invasive most of the in this are on invasive pulmonary The of this disease and to therapy in to the and to to for clinical trials have and will to as clinical trials such as the of and Diseases the for and of and and to of previous trials and the and to a evidence of in and Aspergillus species from by from the from a and rarely Aspergillus species. The of Aspergillus are by and and it would be to include these in the initial invasive disease is Aspergillus are to from those of of and some other Aspergillus species from of the (e.g., and are a of in the but may invasive disease in the immunocompromised The may be as as in patients with or studies may include such as or on on include the of a lung initially by or an the the of a lung caused by of These studies may and the of in neutropenic patients, but the are not because other infections and may The have been in neutropenic commonly chest the more specific and chest should be considered in patients with a infection. resolution or may an with of the by has and for invasive aspergillosis in immunocompromised patients (BII). or are (CIII). of have been useful such are Because of the of the a definitive of disease caused by Aspergillus is The use of against Aspergillus to invasive aspergillosis has in are frequently or more isolated but specific recommendations about frequency of have not been have been developed to Aspergillus in and by and These more and with an available in for of Aspergillus reported of and of largely among in in some studies with that case to be has been in some studies with In some more among the and more in are for use in the In that use have been reported to the of Aspergillus species the in the of Aspergillus species and a in the of and may more of these have been with in trials of invasive aspergillosis, and must be There is also in such as or for of invasive are with some but not evidence of invasive pulmonary and treatment may need to be initiated at that in the more immunocompromised or to or the should in such an empirical treatment The optimal duration of therapy is and on the of invasive aspergillosis, the to therapy, and the underlying or course would be to therapy to treat clinical and are can be are and reversible underlying predispositions have (BIII). of therapy should be by clinical any of antifungal therapy chemotherapy, or of antifungal therapy in patients with who are about to chemotherapy, is of The of these patients to antifungal therapy is largely related to such as the resolution of and the of and the of function from a or organ as as the of aspergillosis Intravenous therapy may be at in patients who are because drug is certain (BIII). B has been the of treatment in invasive aspergillosis, for life-threatening and infections. In patients, the has been to all because of underlying of resolution of or underlying of duration of and other with in made in other a is more likely with in The lipid-based formulations are indicated for patients with invasive aspergillosis who nephrotoxicity while receiving amphotericin B (AII). The lipid-based preparations may be as initial therapy in patients with renal function or in patients receiving other The studies on the preparations have been or with amphotericin B comparative clinical trials amphotericin B and a specific lipid-based for invasive aspergillosis, or specific doses of to be or have been thus Although most studies have that doses of the preparations are to therapeutic to deoxycholate a has the doses are Itraconazole has been as therapy for invasive aspergillosis in studies which found of and These are of has been reported in may be among the immunocompromised The oral is an alternative to amphotericin in patients who are likely to to therapy, to have with and who are not receiving drugs that with itraconazole or which be and attractive would be to use iv therapy (e.g., amphotericin at disease is and with oral therapy for prolonged treatment (CIII). has been used in an of invasive aspergillosis with in studies has been that a triazole with any amphotericin B for invasive aspergillosis. therapy that amphotericin B with or has in and in has also been in and in has with limited in case but the of or efficacy of such has not been in invasive aspergillosis. In may in patients with and levels may be amphotericin is owing to the to function of the of may have significant drug owing to in who are receiving or and this also the of itraconazole use for Surgical has been successful for some of pulmonary prompt surgery as a for the the because of the of pulmonary such as such as or are for prophylaxis or therapy, in the neutropenic or immunocompromised host, but are not for therapeutic use (CIII). of increased survival has not been demonstrated with any of these modalities. to Aspergillus species at other are pulmonary and treatment trials are with most reported treatment In this the therapeutic recommendations are based on of or series, in to from the of infections at more such as lung infections. Aspergillus infections may or may not be invasive and can a or an course The disease manifestations and the subsequent treatment may also depending on the of of the invasive is the of aspergillosis that in the immunocompromised These infections are by with and of in to is from in patients with in who are therapy, to to in patients with or those transplantation of suspicion is in immunocompromised patients. Although are of or limited should be considered in these patients. is and the of new such as a in a host, or an should to including of the and subsequent of are not to but also to Aspergillus infections from those caused by other such as those to or species of by corticosteroid or resolution of the most that should with surgical (BIII). Although surgical alone may be in it may mortality among patients with surgery has been used for in which an is in an to with as as is more extensive surgery is indicated there is of the or or or is (BIII). amphotericin B or has been used by some invasive infections occur in hosts in with levels of such as the and other or and in patients with in other flavus is the most agent of these in to the of from of in immunocompromised These infections have a clinical course to with of the the and subsequent and with acute invasive infections in treatment of surgical and which is in the majority of (BIII). The of antifungal therapy is (CIII). this are Aspergillus infections may also as a or These to a for to with and no invasive surgical removal of the to ensure adequate antifungal therapy has no in these infections (CIII). The is Aspergillus species are a cause of allergic which in with a of allergic from is in of in the of the and is surgical with as for (BIII). antifungal therapy is not used there is evidence of or (CIII). corticosteroids and may be used for There may be a potential for corticosteroids with allergic in to surgery and in the there is a in corticosteroid use is because of corticosteroid of and of the and The of of Aspergillus of the have been reported in immunocompromised such as patients with or AIDS, organ or patients receiving chronic corticosteroid therapy that has commonly been limited to the has been in and lung or have been in patients who with and to this has rarely been reported antifungal therapy has been the of treatment in these Although amphotericin B may have a as therapy In the several reported of surgical or has been for a successful in to antifungal therapy. in the of Aspergillus with the of a in the removal of the by procedure may be given the of antifungals the infections. invasive and infections have been Aspergillus species may the in the with no infection. invasive of the has been in patients with and in patients with acute Aspergillus may Aspergillus In immunocompromised patients, antifungal therapy appears (BIII). infections of or those that occur in patients may be with including removal (BIII). variety of such therapeutic has been which amphotericin B and In these prolonged therapy may be infections. Aspergillus may occur by several including by surgical such as or by which is most commonly in immunocompromised patients, drug or patients with Aspergillus in these and of of amphotericin B and itraconazole the and is inadequate and treatment is Because of amphotericin B may be of in are that of serum experience with this agent in infections is may be for the and of these in with amphotericin B or amphotericin B (BIII). Other manifestations of Aspergillus infections are may be with surgery and amphotericin B it is not antifungal therapy is in these have been used for including the of with amphotericin B amphotericin B amphotericin B or Oral itraconazole may also a in these more since this agent the is there is while the patient is receiving therapy or there is a of Surgical include of a a to the from or or to or may be infections. Aspergillus infections of the may as or an or a The published that mortality in occur as a of with subsequent of and of these is to Aspergillus infections from those caused by other such as or which may of antifungal therapy has been reported to be in some surgical for of the agent with removal of which may not be by antifungals for have also been used Although surgery alone may be in the of in immunocompromised patients, antifungal therapy is also used in the majority of (BIII). in with amphotericin may have a because of There are of with itraconazole, or may be Aspergillus is are reported in drug or or patients on prolonged corticosteroid therapy. may as an of as a of therapy or in the surgery and rarely in patients with no underlying Aspergillus may be in the and may be used for of the course of therapy and (e.g., an amphotericin B has been used for the treatment of these infections as has itraconazole and of may be caused by Aspergillus are to a of such as in a Surgical with therapy is indicated for these infections (BIII). infections. The for Aspergillus infections is by by a surgical or in patients with the those with chronic or drug or is the most caused by Aspergillus with infections Surgical is for these infections. Although an case may be by surgical antifungal therapy is used in B levels in are which may the of drugs that have such as or Itraconazole and has also been used infections. infections caused by Aspergillus species are commonly a of from a of most the which in highly immunocompromised patients. These may be or may not be and occur most commonly on the They as and a with an that is by a Although this is of Aspergillus the is not and a with is indicated to other infections that may in a The majority of infections are caused by fumigatus, or terreus, more Aspergillus has been reported to cause which and in invasive infections to Aspergillus species have been reported in with for which are with Aspergillus These to of of may may also by Aspergillus species. may be caused by Aspergillus species. The of of for a definitive has been antifungal therapy is the of therapy and the are Surgical may be the be in the neutropenic In removal of the in to antifungal therapy is indicated aspergillosis and infections are by surgical in to therapy. Oral itraconazole, with or without therapy, such as is used for infections and Aspergillus species have been reported as a cause of and which is a of aspergillosis. The is rarely isolated from The are and and a of Because of the of amphotericin B the in to the of surgical with is in the of amphotericin B appears case has been with amphotericin B and alone is a of may from of a or from the with or of the may useful in diagnosis. of patients with or have been of antifungal therapy and including appropriate may be as an isolated or with infections. infections are a of that the renal are more in immunocompromised such as patients with or chronic or drug and patients with are at for infections that the renal The of a renal with or without a also occur antifungal therapy is used for of and surgical removal may be indicated. Therapy is by the in by itraconazole or or disease has been with amphotericin B or preparations the of may be since this agent in the with amphotericin B has also been used for and renal infections. infections. antifungal therapy is for aspergillosis The of this with amphotericin B therapy has been this amphotericin or itraconazole, of which in should be Aspergillus has as a of chronic removal is for these infections therapy should be used in and amphotericin B have been as has itraconazole organ with Aspergillus species most in the of infection. The is the most of in the the and in these may in or therapy is but the is infections. Aspergillus species may cause of In to antifungal therapy, surgical of the may be to the infection. aspergilloma. aspergilloma can be as a a pulmonary or of Aspergillus with and have underlying pulmonary disease such as sarcoidosis, or or lung disease The of aspergilloma is made without a lung and the chest are of importance in the diagnosis. pulmonary aspergilloma appears as a of a or and from the of the by an of and is The of an aspergilloma is made the are found in a patient with serum that are for an Aspergillus a with for aspergilloma some patients who corticosteroids may be Although aspergillomas are of as saprophytic of the lung with the manifestations of Aspergillus lung disease with a and Invasive pulmonary aspergillosis may from an aspergilloma and is chronic of Aspergillus has been in which symptoms (e.g., and are an aspergilloma is on chest radiograph, and evidence of is found on of lung is a of aspergilloma and may in is the cause of in to of patients with aspergilloma that aspergilloma on preventing life-threatening hemoptysis, patients with symptoms are candidates for therapy. have been that suggest a with aspergilloma. These include the of the underlying lung increasing or of aspergillomas on chest increasing Aspergillus-specific IgG titers underlying and Although not it that patients who have an of would be at of a life-threatening There is no consensus the treatment of aspergilloma. or randomized trials have been treatment have been from trials and case The decision in the of aspergilloma is therapy is Since life-threatening in a of patients, it may be to all patients with aspergilloma to therapy, since therapy is with significant morbidity and treatment for aspergilloma is surgical surgery has been with a morbidity and mortality is owing to the of and the of of the mortality is and such as and are that to the surgical of is that aspergillomas to in with pulmonary function in patients, surgery is because of underlying pulmonary has been that surgical of aspergilloma be to patients with and adequate pulmonary function and considered for patients with underlying sarcoidosis, immunocompromised patients, and those with increasing Aspergillus-specific IgG titers (CIII). The course of the in the of surgery about surgical Bronchial artery embolization has been used to the that the in patients from aspergilloma other are in and can be is or and a patient who can for from the pulmonary and to the will not be successful should be considered as a temporizing procedure in a patient with life-threatening hemoptysis, who be for more definitive therapy the (BIII). for aspergillomas have therapy intracavitary or instillation of antifungal antifungals and antifungals symptoms (e.g., or are may be related in to with agent or to allergic has been in patients with evidence of (e.g., IgE and given corticosteroid therapy such therapy the of to invasive or disease of an infection. of these studies Intravenous amphotericin B for aspergilloma provided no pulmonary that used or intracavitary instillation of amphotericin B for aspergilloma of patients resolution or clinical is more in the patient with pulmonary The use of itraconazole for aspergilloma has been reported in several studies of these studies and not a the dose and duration of itraconazole therapy not the of these studies suggest that itraconazole may be in the treatment of aspergilloma (BIII). is a disease of the caused by initially as a disease by pulmonary and and or for ABPA proposed to Aspergillus to Aspergillus serum of pulmonary or and The of ABPA likely the and the of all made the certain of Aspergillus in by use of a of of or specific IgE directed against Aspergillus to Aspergillus and on with ABPA has been reported to be in of patients with in the patients with have with Aspergillus and ABPA these patients may be at for invasive aspergillosis lung transplantation is the chest in ABPA of that in the and may be These are commonly caused by with The with may a or a These are a of the disease and may be by a or may be on chest The of ABPA should be considered in a asthmatic or an asthmatic with any of the ABPA may clinical of acute to to lung disease with lung Therapy in ABPA is directed at acute asthmatic exacerbations and of Although corticosteroid therapy is the of therapy for ABPA, there is a paucity of data The studies of corticosteroids for ABPA have numbers of patients and have been nor and the corticosteroid dose has despite these data support the of corticosteroids in the of acute ABPA (AII). ABPA patients with mg/kg/d of for 1 followed by other made to The symptoms of and rapidly with this the dose of most patients developed symptoms of that with corticosteroids in most IgE levels with disease since with a clinical to corticosteroids and increased exacerbations of There have been studies that the treatment of chronic ABPA with and all have been ABPA patients for and found that patients a chronic course by pulmonary with in lung not a to as several asymptomatic patients developed and lung that in chronic lung doses in episodes of patients with pulmonary of ABPA patients given chronic corticosteroid therapy likely to those given These found that of for an to the of pulmonary the clinical course of patients with ABPA a of of with at a dose of There no significant in spirometry the These data are since pulmonary function not the a would be to the by a in a Increasing serum IgE levels, new or worsening infiltrate on chest radiograph, and worsening spirometry suggest that corticosteroids are (BII). Multiple asthmatic exacerbations in an ABPA patient suggest that corticosteroid therapy should be at a dose of of (BIII). The decision to the of corticosteroids should be made on an individual basis, depending on the clinical course (BIII). to the treatment of ABPA is to Aspergillus species from the and oral are not in preventing In a Aspergillus-specific IgG and symptoms in ABPA patients. subsequent of an that not randomized no from trials have indicated that itraconazole is useful as therapy in ABPA, because the corticosteroid dose can be pulmonary function is and IgE levels recently for ABPA that itraconazole, for in significant in to as by the in corticosteroid dose and IgE and the in and in pulmonary Itraconazole may be useful as a agent (BII). corticosteroids not to be for ABPA some this may be a useful in some patients and suggest doses may be in to with exacerbations of ABPA there have been no studies of to ABPA, and the of such therapy therapy or of in the have not been

HYPERTENSIVE heart disease can be defined as the response of the heart to the afterload imposed on the left ventricle by the progressively increasing arterial pressure and total peripheral resistance produced by hypertensive vascular disease. Although the response sometimes appears to be out of proportion to the level of the arterial pressure, it is primarily the result of the hemodynamic overload. Hypertension can cause or is related to various cardiac manifestations, among them left ventricular hypertrophy, congestive heart failure, cardiac dysrhythmias, and ischemic heart disease. Although the risk of atherosclerotic coronary heart disease is related to the systolic and diastolic . . .

Exposure of rats to hypoxia (7% O2) markedly increased the level of heme oxygenase-1 (HO-1) mRNA in several tissues. Accumulation of HO-1 transcripts was also observed after exposure of rat aortic vascular smooth muscle (VSM) cells to 1% O2, and this induction was dependent on gene transcription. Activation of the mouse HO-1 gene by all agents thus far tested is mediated by two 5'-enhancer sequences, SX2 and AB1, but neither fragment was responsive to hypoxia in VSM cells. Hypoxia-dependent induction of the chloramphenicol acetyltransferase (CAT) reporter gene was mediated by a 163-bp fragment located approximately 9.5 kilobases upstream of the transcription start site. This fragment contains two potential binding sites for hypoxia-inducible factor 1 (HIF-1). A role for HIF-1 in HO-1 gene regulation was established by the following observations: 1) HIF-1 specifically bound to an oligonucleotide spanning these sequences, 2) mutation of these sequences abolished HIF-1 binding and hypoxia-dependent gene activation in VSM cells, 3) hypoxia increased HIF-1alpha and HIF-1beta protein levels in VSM cells, and 4) hypoxia-dependent HO-1 mRNA accumulation was not observed in mutant hepatoma cells lacking HIF-1 DNA-binding activity. Taken together, these data demonstrate that hypoxia induces HO-1 expression in animal tissues and cell cultures and implicate HIF-1 in this response.

Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time. They can therefore provide information on the long-term safety, particularly pertaining to rare events, and effectiveness of drugs in large heterogeneous populations, as well as information on utilization patterns and health and economic outcomes. This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice.Funding: Sanofi US, Inc.

This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.